• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Virol. Inhibition of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Infection by Anti-CD26 Monoclonal Antibody.

Giuseppe

Emeritus
[Source: US National Library of Medicine, full page: (LINK). Abstract, edited.]


J Virol. 2013 Sep 25. [Epub ahead of print]

Inhibition of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Infection by Anti-CD26 Monoclonal Antibody.

Ohnuma K, Haagmans BL, Hatano R, Raj VS, Mou H, Iwata S, Dang NH, Jan Bosch B, Morimoto C.

Source: Department of Therapy Development and Innovation for Immune disorders and Cancers, Graduate School of Medicine, Juntendo University, 2-1-1, Hongo, Bunkyo-ku, Tokyo 113-8421, Japan.


Abstract

We identified the domains of CD26 involved in binding of Middle East respiratory syndrome coronavirus (MERS-CoV) using distinct clones of anti-CD26 mAbs. Especially one clone, named 2F9, almost completely inhibited viral entry. The humanized anti-CD26 mAb YS110 also significantly inhibited infection. These findings indicate that both 2F9 and YS110 are potential therapeutic agents for MERS-CoV infection. In particular, YS110 is a good candidate for immediate testing as a therapeutic modality for MERS.


PMID: 24067970 [PubMed - as supplied by publisher]


-
-------
 
Back
Top